In an interview with the Journal of Clinical Pathways, IVI's Jennifer Bright and Mark Linthicum discuss how IVI is transforming value assessment. Read the transcript from the interview here.
In an op-ed published by Fierce Healthcare, Director of Scientific Communications, Mark Linthicum discusses current shortfalls of value assessment and what is needed to move to value assessment 2.0. Read the full article here.
In a recent post on the IVI-sponsored Health Affairs featured blog series, IVI's Executive Director, Darius Lakdawalla, and Anupam Jena recommend that creators of value frameworks recognize the unique issues associated with valuing treatments for rare diseases by adopting societal, as well payer-oriented perspectives. Included in this assessment are the important roles of treatment spillovers, societal preferences about health [...]
In his letter to the editor published in the Journal of Clinical Oncology, IVI's Evidence Synthesis Expert, Jeroen Jansen, argues that network meta-analysis is the only transparent framework to help answer the treatment selection question. Responding to his letter, members of the ASCO Task Force reply that Dr. Jansen makes a "strong argument for the use [...]
In a recent post on the IVI-sponsored Health Affairs featured blog series, the National Pharmaceutical Council's Robert Dubois (also member of IVI Strategic Advisory Panel) and Kimberly Westrich examine current value assessment models' readiness for use in healthcare decision-making. Applying NPC's 35 Guiding Practices, they conclude that all existing frameworks possess individual strengths and weaknesses, but [...]
How New Value Frameworks Can Undermine the Ability of Patients and Providers to Find the Best Treatment
In Tomas Philipson's latest Forbes.com op-ed, he and co-author Jason Shafrin (IVI Director of Research) describe the potential for new value frameworks to undermine the ability of patients and providers to find the best treatment for a specific patient. Read the full article here.
Amitabh Chandra, Jason Shafrin (IVI Director of Research), and Ravider Dhawan examine the utility of cancer value frameworks in the latest edition of the Journal of the American Medical Association (JAMA). Read the full abstract here.